Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

836.15 +25.91 (+3.20%)
Streaming Delayed Price Updated: 11:10 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
News headline image
Is This Biotech Stock a Buy After a Groundbreaking Approval? ↗
This milestone came with an asterisk. 
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Regeneron’s Q1 Earnings Call
Regeneron's first quarter performance delivered revenue and non-GAAP earnings per share above Wall Street expectations, as management cited strong commercial... 
Via StockStory
Topics Earnings
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? ↗
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment. 
Via The Motley Fool
Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q1 Estimates, But Stock Slips on Margin Headwinds and Manufacturing Glitch ↗
Via Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN) Emerges as a 'Decent Value' Biotech Pick ↗
Via Chartmill
News headline image
1 Cash-Producing Stock Worth Investigating and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings ↗
Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analysts have mixed views on the stock. 
Via Benzinga
News headline image
REGN Q1 Deep Dive: Product Expansion Drives Growth, Margin Pressures Draw Scrutiny
Biotech company Regeneron (NASDAQ:REGN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 19% year on year to $3.61 billion... 
Via StockStory
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a... 
Via StockStory
News headline image
Why Regeneron (REGN) Shares Are Getting Obliterated Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 7.1% in the afternoon session after its first-quarter 2026 earnings report revealed sig... 
Via StockStory
Topics Artificial Intelligence World Trade
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Regeneron (REGN) Q1 2026 Earnings Transcript ↗
Regeneron (REGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 19% year on year to $3.61 billion. I... 
Via StockStory
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron (REGN) Q1 Earnings Report Preview: What To Look For
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Wednesday morning. Here’s what to expect. Regeneron beat analysts’ revenue expectatio... 
Via StockStory
Topics Artificial Intelligence
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
It will be a turbulent ride, but patient investors might come out of it much richer. 
Via The Motley Fool
News headline image
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
AbbVie is making progress in this market, but it is still far behind the leader. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.